Satellos Bioscience (MSLE) Net Income (2025 - 2026)
Satellos Bioscience (MSLE) posted quarterly Net Income of -$9.8 million for Q1 2026, down 259.06% year-over-year from $6.1 million in Q1 2025, and down 259.06% quarter-over-quarter from $6.1 million in Q1 2025.
Satellos Bioscience (MSLE) Net Income (2025 - 2026) Analysis & Trends
Satellos Bioscience (MSLE) has reported Net Income for 2 consecutive years, with -$9.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Income fell 259.06% year-over-year to -$9.8 million; the TTM figure through Mar 2026 stood at -$3.6 million (changed N/A YoY), while the FY2025 annual figure was -$25.0 million, down 23.54% from the prior year.
- Net Income retreated to -$9.8 million in Q1 2026 per MSLE's latest filing, from $6.1 million in the prior quarter.
- Across five years, Net Income topped out at $6.1 million in Q1 2025 and bottomed at -$9.8 million in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.60 Bn | 130.75 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.93 Bn | 77.93 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 65.06 Bn | 59.88 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 56.22 Bn | 51.08 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 42.03 Bn | 36.93 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.65 Bn | 28.34 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 27.70 Bn | 9.31 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.48 Bn | - | 81.49 Mn |
| 10 | Satellos Bioscience | 207.48 Mn | 207.48 Mn | - | -11.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9.77 Mn |
| Mar 31, 2025 | 6.14 Mn |